Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical (ICCM) has disclosed Current Deferred Revenue for 4 consecutive years, with $255000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 23.65% to $255000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $255000.0 through Dec 2025, down 23.65% year-over-year, with the annual reading at $255000.0 for FY2025, 23.65% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $255000.0 at IceCure Medical, down from $334000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $646000.0 in Q4 2022, with the low at $187000.0 in Q4 2023.
  • Average Current Deferred Revenue over 4 years is $355500.0, with a median of $294500.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue crashed 71.05% in 2023, then soared 78.61% in 2024.
  • Over 4 years, Current Deferred Revenue stood at $646000.0 in 2022, then plummeted by 71.05% to $187000.0 in 2023, then skyrocketed by 78.61% to $334000.0 in 2024, then dropped by 23.65% to $255000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $255000.0, $334000.0, and $187000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.